CAMBRIDGE, Mass., Feb. 17, 2026 /PRNewswire/ -- Sanofi today announced the appointment of Manuela Buxo as Head of Specialty Care, effective March 1, 2026. Manuela will succeed Brian Foard, who has decided to leave the company as of February 28, 2026, having accepted an external leadership opportunity.

Brian joined Sanofi in 2017 and has held several senior leadership roles, most recently leading the Specialty Care Global Business Unit and serving as a member of the Executive Committee. During his tenure, Sanofi's Specialty Care strengthened its global position, driven by the launches of key medicines such as Dupixent across multiple indications and geographies.

Manuela will lead Sanofi's Specialty Care Global Business Unit and serve as a member of the Executive Committee. Based in Cambridge, Mass., Manuela currently leads Sanofi's Global Immunology Alliance Franchise and oversees its worldwide strategy and performance. For more than two years, she has driven the global expansion and growth of Dupixent. With over 20 years of international healthcare experience and prior leadership roles across Specialty Care in Europe and global franchise management, Manuela brings deep operational knowledge of the business and strong familiarity with key markets and medicines. Her experience, as well as her knowledge of the company and its people, will further drive the dynamic development of Specialty Care.

Olivier Charmeil, designated interim Chief Executive Officer, Sanofi, said: "I have greatly valued the opportunity to work with Brian over the years and thank him for his leadership and contributions to Sanofi. We wish him every success in the new role he has decided to pursue at this stage of his career. As we move forward, Manuela brings deep experience, longstanding commitment to Sanofi, and a thorough understanding of our Specialty Care portfolio and priorities. I am confident she will ensure strong continuity for the business while maintaining the momentum we have built and ensuring the organization continues to move with focus and speed."

Sanofi remains committed to advancing its Specialty Care priorities and ensuring continuity of execution during this transition.

About Sanofi

Sanofi is an R&D driven, AI-powered biopharma company committed to improving people's lives and delivering compelling growth. We apply our deep understanding of the immune system to invent medicines and vaccines that treat and protect millions of people around the world, with an innovative pipeline that could benefit millions more. Our team is guided by one purpose: we chase the miracles of science to improve people's lives; this inspires us to drive progress and deliver positive impact for our people and the communities we serve, by addressing the most urgent healthcare, environmental, and societal challenges of our time.

Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY

Media Relations

Evan Berland | +1 215 432 0234 | evan.berland@sanofi.com

Victor Rouault | +1 617 356 4751 | victor.rouault@sanofi.com

Timothy Gilbert | +1 516 521 2929 | timothy.gilbert@sanofi.com

Ekaterina Pesheva | +1 410 926 6780 | ekaterina.pesheva@sanofi.com

Sandrine Guendoul | +33 6 25 09 14 25 | sandrine.guendoul@sanofi.com

All trademarks mentioned in this press release are the property of the Sanofi group.

U.S. INDICATIONS

DUPIXENT is a prescription medicine used:

   -- to treat adults and children 6 months of age and older with 
      moderate-to-severe eczema (atopic dermatitis or AD) that is not well 
      controlled with prescription therapies used on the skin (topical), or who 
      cannot use topical therapies. DUPIXENT can be used with or without 
      topical corticosteroids. It is not known if DUPIXENT is safe and 
      effective in children with AD under 6 months of age. 
 
   -- with other asthma medicines for the maintenance treatment of 
      moderate-to-severe eosinophilic or oral steroid dependent asthma in 
      adults and children 6 years of age and older whose asthma is not 
      controlled with their current asthma medicines. DUPIXENT helps prevent 
      severe asthma attacks (exacerbations) and can improve your breathing. 
      DUPIXENT may also help reduce the amount of oral corticosteroids you need 
      while preventing severe asthma attacks and improving your breathing. It 
      is not known if DUPIXENT is safe and effective in children with asthma 
      under 6 years of age. 
 
   -- with other medicines for the maintenance treatment of 
      chronic rhinosinusitis with nasal polyps (CRSwNP) in adults and children 
      12 years of age and older whose disease is not controlled. It is not 
      known if DUPIXENT is safe and effective in children with CRSwNP under 12 
      years of age. 
 
   -- to treat adults and children 1 year of age and older with eosinophilic 
      esophagitis (EoE), who weigh at least 33 pounds (15 kg). It is not known 
      if DUPIXENT is safe and effective in children with EoE under 1 year of 
      age, or who weigh less than 33 pounds (15 kg). 
 
   -- to treat adults with prurigo nodularis (PN). It is not known if DUPIXENT 
      is safe and effective in children with PN under 18 years of age. 
 
   -- with other medicines for the maintenance treatment of adults with 
      inadequately controlled chronic obstructive pulmonary disease (COPD) and 
      a high number of blood eosinophils (a type of white blood cell that may 
      contribute to your COPD). DUPIXENT is used to reduce the number of 
      flare-ups (the worsening of your COPD symptoms for several days) and can 
      improve your breathing. It is not known if DUPIXENT is safe and effective 
      in children with COPD under 18 years of age. 
 
   -- to treat adults and children 12 years of age and older with chronic 
      spontaneous urticaria (CSU) who continue to have hives that are not 
      controlled with H1 antihistamine treatment. It is not known if DUPIXENT 
      is safe and effective in children with CSU under 12 years of age, or who 
      weigh less than 66 pounds (30 kg). 
 
   -- to treat adults with bullous pemphigoid $(BP)$. It is not known if DUPIXENT 
      is safe and effective in children with BP under 18 years of age. 

DUPIXENT is not used to relieve sudden breathing problems and will not replace an inhaled rescue medicine or to treat any other forms of hives (urticaria).

IMPORTANT SAFETY INFORMATION

Do not use if you are allergic to dupilumab or to any of the ingredients in DUPIXENT$(R)$ .

Before using DUPIXENT, tell your healthcare provider about all your medical conditions, including if you:

   -- have eye problems. 
 
   -- have a parasitic (helminth) infection. 
 
   -- are scheduled to receive any vaccinations. You should not receive a "live 
      vaccine" right before and during treatment with DUPIXENT. 
 
   -- are pregnant or plan to become pregnant. It is not known whether DUPIXENT 
      will harm your unborn baby. 
 
          -- A pregnancy registry for women who take DUPIXENT during pregnancy 
             collects information about the health of you and your baby. To 
             enroll or get more information call 1-877-311-8972 or go to 
             https://mothertobaby.org/ongoing-study/dupixent/. 
 
   -- are breastfeeding or plan to breastfeed. It is not known whether DUPIXENT 
      passes into your breast milk. 

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

Especially tell your healthcare provider if you are taking oral, topical, or inhaled corticosteroid medicines; have asthma and use an asthma medicine; or have AD, CRSwNP, EoE, PN, COPD, CSU, or BP and also have asthma. Do not change or stop your other medicines, including corticosteroid medicine or other asthma medicine, without talking to your healthcare provider. This may cause other symptoms that were controlled by those medicines to come back.

DUPIXENT can cause serious side effects, including:

   -- Allergic reactions. DUPIXENT can cause allergic reactions, including skin 
      reactions, that can sometimes be severe. Stop using DUPIXENT and tell 
      your healthcare provider or get emergency help right away if you get any 
      of the following signs or symptoms: breathing problems or wheezing, 
      swelling of the face, lips, mouth, tongue or throat, fainting, dizziness, 
      feeling lightheaded, fast pulse, fever, hives, skin rash, including rash 
      that looks like a bullseye, painful red or blue bumps under the skin, or 
      red pus-filled spots on the skin, general ill feeling, itching, swollen 
      lymph nodes, nausea or vomiting, joint pain, or cramps in your 
      stomach-area. 
 
   -- Eye problems. Tell your healthcare provider if you have any new or 
      worsening eye problems, including eye pain or changes in vision, such as 
      blurred vision. Your healthcare provider may send you to an 
      ophthalmologist for an exam if needed. 
 
   -- Inflammation of your blood vessels. Rarely, this can happen in people 
      with asthma who receive DUPIXENT. This may happen in people who also take 
      a steroid medicine by mouth that is being stopped or the dose is being 
      lowered. Tell your healthcare provider right away if you get: rash, chest 
      pain, worsening shortness of breath, brown or dark colored urine, 
      persistent fever, or a feeling of pins and needles or numbness of your 
      arms or legs. 
 
   -- Psoriasis. This can happen in people with atopic dermatitis and asthma 
      who receive DUPIXENT. Tell your healthcare provider about any new skin 
      symptoms. Your healthcare provider may send you to a dermatologist for an 
      examination if needed. 
 
   -- Joint aches and pain. Some people who use DUPIXENT have had trouble 
      walking or moving due to their joint symptoms, and in some cases needed 
      to be hospitalized. Tell your healthcare provider about any new or 

(MORE TO FOLLOW) Dow Jones Newswires

February 17, 2026 08:30 ET (13:30 GMT)